STUDIES AND SURVEYS ON FISHWAYS AND FISH MIGRATION AT THE NAGARAGAWA ESTUARY BARRAGE

KAMIMURA JUICHI,SAKAI SUSUMU,SANEMATSU TOSHIRO 한국수자원학회 2005 한국수자원학회 학술대회 Vol.2005 No.1

Poster Session : PS 0330 ; Hematology : Experience of Chemotherapy of Malignant Lymphoma in More Than 90 Years

( Kazuhiko Natori ),( Susumu Ishihara ),( Daisuke Nagase ),( Yukitoshi Toyoda ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: Chemotherapy of the elderly person was common practice. Clinical outcome is force to equal an adult. However, a patient 90 years or older has a high risk of chemotherapy. We report our experience with two patients of malignant lymphoma 90 years or older. Methods: In periods from 2003 to 2013, patients whom malignant lymphoma was diagnosed in our hospital, we extracted a case 90 years or older. We reviewed gender, clinical stage, chemotherapy, dosage, clinical outcome, and prognosis. Results: Case 1: 91-year-old male, fi rst manifestation was systemic lymphadenopathy, Sufferings from dyspnea, he became the hospitalization. Pleural effusion was revealed, after lymph node biopsy, he was diagnosed non-Hodgkin`s lymphoma diffuse large B cell (NHL DLBCL). We performed chemotherapy by his strong wish. After 3 course of R-CHOP (dosage 50%), he achieved partial remission and was able to return to the house. He died after a diagnosis in 13 months. Case 2: 90-year-old female, fi rst manifestation was dysfunction of artifi cial denture, she had a checkup in dentistry. At the time dentist discovered a mass lesion and performed biopsy. Diagnosis was NHL DLBCL, and she was referred and had performed chemotherapy our hospital. After 6 course of R-CHOP (dosage 65%), she achieved complete remission and he still alive. Conclusions: It is got enough cinical outcome from even a case 90 years or older bychemotherapy. However, drug reduction criteria are not established that are indispensable for safe chemot

Poster Session:PS 0224 ; Gastroenterology : HBV Infection Screening for Malignant Lymphoma

( Kazuhiko Natori ),( Susumu Ishihara ),( Daisuke Nagase ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: Malignant lymphoma(ML) is the ninth place cause of death in Japan and chemotherapy(CTx) is fi rst choice. Side effect of CTx, rituximab, reactivation of the Hepatitis B type virous(HBV) is serious problem. We reviewed the situation of the HBV infection check of patients that was performed CTx. Methods: We intended for patient which ML was diagnosed in our hospital from January 2003 to December, 2012. The pretreatment HBV check factor is hepatitis B surface antigen(HBsAg), hepatitis B surface antibody(anti-HBs), antihepatitis B core antibody(anti-HBc). When either anti-HBs or anti-HBc is positive, we measure viral amount by HBV-DNA Taqman. In the case of HBV check is imcomplete, additional HBV check followed as much as possible. We reviewed positive rate of HBsAg, anti-HBs, anti-HBc. Also we investigated HBV reactivation rate of R+CTx. Results: All cases were 446 cases, about type of malignant lymphoma, Hodgkin`s lymphoma(HL) 39 cases, non-Hodgkin`s lymphoma(NHL) 401 cases, Adult T cell Lymphoma( ATL) 6 cases. Among 446 patients, 411 cases received CTx or CTx+radiation therapy(RTx). HBsAg was examined in all cases, anti-HBs, anti-HBc was 351 cases, 261 cases respectively. The case searched three factors before CTx was 150 cases. 30 cases were searched HBV-DNA Taqman that indicated anti-HBs and/or anti-HBc were positive. In theses cases, treatment needed situation were 5 cases. These 5 cases treated by entecavir and after 2 weeks, CTx performed. The case that already given an antiviral drug with HBsAg positive for treatment was 4 cases. 107 cases were searched anti-HBs, anti-HBc or either after CTx. 2 cases was revealed to have needed the administration of antiviral drug. HBV reactivation rate was 0%. Conclusions: Only 2 cases needed therapy for HBV infection that were revealed after CTx. We do check in all cases and try for safe chemotherapy especially rituximab including regimen.

Poster Session : PS 0327 ; Hematology : Multiple Neoplasms Including Myelodysplastic Syndrome

( Kazuhiko Natori ),( Susumu Ishihara ),( Daisuke Nagase ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: The myelodysplastic syndrome is blood stem cell disease and in many cases, have cytogenetic abnormality. And myelodysplastic syndrome has characteristic that there is defi ection in elderly. But progress of therapy and supporting therapy improved a prognosis. The possibility that a survivor had the second malignancy rise. we reviewed multiple neoplasms including the myelodysplastic syndrome and we report. Methods: In the case that hematologic malignancy was diagnosed in our hospital from 1988 to 2012, we intended for double cancer 271 cases including hematological malignancy. We reviewed 43 multiple neoplasms including the myelodysplastic syndrome. The examination factors are type of the hematological malignancy, treatment, gender, interval with the second cancer. Results: All cases are 43 cases, including male 29 cases, female 14 cases, type of multiple neoplasms, double 40 cases, triple 3 cases, kind of multiple neoplasms, metachronous 31 cases, synchronous 12 cases. The malignancies to constitute multiple neoplasms with myelodysplastic syndrome are gastric cancer 11 cases, esophangeal carcinoma 5 cases, breasr cancer 3 case, multiple myeloma 6 cases, non-Hodgkin`s lymphoma 3 cases, colon cancer 5 cases, lung cancer 4 cases, renal carcinoma 2 cases, urinary bladder carcinoma 2 cases, prostate carcinoma 1 case, thyroid cancer 1 case, pharyngeal cancer 1 case, laryngeal cancer 1 case, angiosarcoma 1 case. On the other hand, acute myelogeneous leukemia, therapy-related leukemia are11 cases, de novo myelodysplastic syndrome 32 cases. Conclusions: The survivors by the fi rst cancer therapy are paid attention to therapy- related myelodysplastic syndrome.

Poster Session : PS 0339 ; Hematology : Study of Multiple Neoplasms Including Hematological Malignancies and Lung Cancer

( Daisuke Nagase ),( Susumu Ishihara ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ),( Kazuhiko Natori ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: It is a well-known fact that the prevalence of malignancy increases year by year. In addition, other malignancies may be found in the systemic screening before treatment or after several therapy during observation. Malignant lymphoma is often the most number of patients. We reviewed the complication with lung cancer that was a poor prognosis. We look for possibility of the prognosis improvement by determining a characteristic. Methods: In 290 cases multiple cancer including hematological malignancy in our department, we examined 20 cases that including lung cancer & malignant lymphoma. Reviewed the following is gender, age, outbreak style, strategy of therapy, clinical income, and overall survival. Diagnostic criteria of multiple cancer is according to Warren&Gates. It was distinguish synchronous and metachronous that synchronous double cancer diagnosed interval of 6 months. Results: The subjects were 20 patients, median age was 70 years. Synchronous cancer was found in 5 patients and metachronous in 15 patients. Malignant lymphoma was non-Hodgkin`s lymphoma in 11 patients, Hodgkin`s lymphomain 2 patients and lymphoma- stage mycosis fungoides in 1patient. Acute myelogeneous leukemia 3 cases, myelodysplastic syndrome 3 cases. All of the patients with ML underwent chemotherapy (CTx) and 8 and 4 of them achieved completeand partial remission, respectively, while 2cases had progressive disease. In 20 cases with LC, operation (Ope) alone was conducted in 6 cases, Ope+ adjuvant therapy in 3 cases, radiation therapy (RTx) in 1case, RTx + CTx in 1case, and CTx alone in 7 cases, non therapy 2 cases. The median survival was 11 months. Conclusions: For metachronous type, there is chance to fi nd second cancer, if they observed long time. I think that we must understand he has or will have another cancer. Prognosis improvement of the advanced lung cancer is expected.

Poster Session : PS 0336 ; Hematology : Hodgkin`s Lymphoma in Our Hospital

( Kazuhiko Natori ),( Daisuke Nagase ),( Susumu Ishihara ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: In Japan, ML is hematological malignancies with much number of cases. non-Hodgkin`s lymphoma(NHL) is more than 90%. There is extremely little number of patients Hodgkin`s lymphoma(HL). In Europe, the rarion between NHL and HL, is almost half and half. So we paid attention to HL and examined. Methods: We intended for patient which ML was diagnosed in our hospital from January 2003 to December, 2012. We studied and reported 38 cases about age, gender, pathological fi ndings, therapy, median survival time, 5 years survival rate. Survival was measured from the diagnosis of multiple cancer to time of death or last contact. Results: All cases were 38 cases, gender ration was male 23 cases, female 16 cases. Median age was 45 years, pathological fi ndings, L-D 1 case, L-P 1 case, L-R 6 cases, MC 15 cases, PHL 1 case, NS 14 cases. About clinical stage, I was 5 cases, II was 15 cases, III was 10 cases, IV was 7 cases. Adult patients were 25 cases, elderly patients were 13 cases. About therapy, more than 65 years old that assumed Bleomycine skipped. ABVD therapy performed 26 cases, ABVD therapy + RTx 1 case, AVD therapy 8 cases, C-MOPP therapy 3 cases. Median survival time was 84 months, and 5 years survival rate was 79. 6%. About age, less than 60 years group did not reach median survival time, median survival time of more than 60 years group was 76 months. There is no signifi cant difference between 2 group. 29 cases were survivor and death cases were 9 cases. Cause of death, 8 cases due to original disease, 1 case another reason( because of lung cancer). Conclusions: HL is good prognosis disease in hematological malignancies, but in more than 60 years patients, there is many problem.

Poster Session : PS 0335 ; Hematology : Study of Non-Hodgkin`s Lymphoma Diffuse Large B Cell Cases That are Treated without Rituximab

( Kazuhiko Natori ),( Daisuke Nagase ),( Susumu Ishihara ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: The strategy of non-Hodgkin`s lymphoma changed dramatiscally, especially in B cell type by rituximab. The pathological fi ndings which showed immunochemical stain CD20 positive cases, rituximab is effective agent about. Some cases did not treat without rituximab several reasons. Methods: From 2003 to 2012, 9 years, we intended for 446 patients whom malignant lymphoma was diagnosed in detail by histopathology. Clinical stage is determinded by Ann Aobor classifi cation. We investigate the cases who do not treat without rituximab about the reason, age, clinical stage, therapy and prognosis. Results: All cases are 69 cases, about gender, male 42 cases, female 27 cases, median age is 71 years ranged 22-89 years. Perfomance Status at diagnosis, 0 grade 20 cases, 1grade 17 cases, 2grade 4 cases, 3grade 10 cases, 4grade 18 cases. About clinical stage by Ann Aobor classifi cation, I is 14 cases that included L-I(Lugano classifi cation), II is 5 cases, III is 9 cases, IV is 41 cases. Strategy of therapy, best supporting care 17 cases, aim to cure 42 case, palliative 11 cases. The reason without rituximab, bestsupporting care 18 cases, another standard therapy 13 cases, CD20 negative 3 cases, Hepatitis B virus active infection 6 cases, Hepatitis C virus active infection 2 cases, palliative therapy 12 cases, infusion reaction 9 cases, much tumor burden 2 cases, avoiding gastrointestinal perforation 2 cases, leukemic state 1 case. Median survival time is 12 months ranged 1-111 months. Conclusions: Rituximab is remarkably improved prognosis about non-Hodgkin`s lymphoma.

Poster Session : PS 0334 ; Hematology : Retrospective Study of the Follicular Lymphoma

( Kazuhiko Natori ),( Daisuke Nagase ),( Susumu Ishihara ),( Akiko Sakai ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: The malignant lymphoma is the ninth place cause of death in Japan. A ratio of non-Hodgkin`s lymphoma(NHL) is overwhelmingly big in malignant lymphoma in Japan. Follicular lymphoma was rather small ratio, not only Asian area but also European area. So we reviewed and report our experience of follicular lymphoma patients. Methods: In periods from 2003 to 2012, 446 patients whom malignant lymphoma was diagnosed in our hospital, we extracted follicular lymphoma. We reviewed gender, clinical stage, chemotherapy, clinical outcome, and prognosis. Results: During studied periods, eligible data for investigation was 58 cases, including female 36, male 22, median age was 62 years. About clinical stage, I 2 cases, II 8 cases, III 14 cases, IV 34 cases, advanced stage was dominant. In treatment strategy, aim to cure standard therapy that rituximab + CHOP or rituximab + CHOP like regimen performed 51 cases, RCHOP regimen 39 cases, RCHO regimen 9 cases, RCHOP like regimen 1case, RCVP regimen3 cases, radiation therapy alone 3 cases. About median survival time dose not reach, 5 years overall survival rate is 85. 8%. Compared between up to stageIII versus IV, each group dose not reach median survival time, and there is not signifi cant difference about survival. 5 years survival rate are 83. 2%, 88. 8% respectively. Cause of death, 7 cases were death, consist of cause of death, 5 cases were due to original disease, 1 case due to heart attack, 1 case due to gastric cancer. Conclusions: The clinical outcome of follicular lymphoma improved by rituximab. But some cases do not effect chemotherapy and not reach complete remission, especially in elderly, organs disfunction are trouble about anti-cancer agent dosage, so insuffi - cient therapy performed. We must manage such cases using new strategy.

Microwave discharge electrodeless lamps (MDEL) Part IV. Novel self-ignition system incorporating metallic microwave condensing cones to activate MDELs in photochemical reactions

Horikoshi, Satoshi,Tsuchida, Akihiro,Sakai, Hideki,Abe, Masahiko,Sato, Susumu,Serpone, Nick Korean Society of Photoscience 2009 Photochemical & photobiological sciences Vol.8 No.11

A metallic condensing cone that concentrates microwave radiation (equivalent to an optical lens) has been developed and used as part of a system to activate a microwave discharge electrodeless lamp (MDEL) in the oxidative treatment of wastewaters by aiding the novel self-ignition of the lamp on irradiation at low microwave power levels. This approach to self-ignition can potentially lead to considerable energy savings in such treatments. System performance was examined for the ignition power of microwaves of such MDEL devices in water, whose usefulness was assessed by investigating the photolytic transformation of aqueous solutions of representatives of three classes of contaminants: chlorinated phenols, herbicides and endocrine disruptors, specifically 4-chlorophenol (4-CP), 2,4-dichlorophenoxyacetic acid (2,4-D) and 4,4'-isopropylidenediphenol (bisphenol-A; BPA), respectively, taken as model wastewaters in air-equilibrated, in oxygen-saturated and in $TiO_2$-containing aqueous media. The results are discussed in terms of the dynamics of the photo-induced degradation processes.

Poster Session : PS 0333 ; Hematology : Multiple Neoplasms Including Malignant Lymphoma

( Kazuhiko Natori ),( Daisuke Nagase ),( Susumu Ishihara ),( Akiko Sakai ),( Yukitoshiq Toyoda ),( Motohiro Kato ),( Yasunobu Kuraishi ),( Kazuho Arai ),( Haruka Izumi ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1

Background: The clinical outcome of the malignant lymphoma improved and longterm survivor increased. In addition, the improvement of the examination technology and available PET/CT, screening ability rose, multiple neoplasms increased drastically last decade. We reviewed multiple neoplasms including the ML which accounted for a major ratio in hematological malignancies. Methods: We were approved privacy policy by the Ethical Review Board. Between January 1988 and December 2013, we reviewed multiple neoplasms including hematological malignancies. The diagnosis of the multiple neoplasms depends on a criteria of Warren & Gates. The defi nition of metachronous type and synchronous type is 6 months interval. Results: During the studied period, 285 cases became the subject of the examination. The multiple neoplasms including the ML was 161 cases in that. Median age was 70 years, male/female ratio was 101/60, double neoplasms were 135 cases, triple neoplasms 24 cases, quadple neoplasms 2 cases. The type of multiple neoplasms, metachrounaous type, synchronous type, were 120 cases, 41 cases respectively. In metachronous double type, all cases were102, and median time of interval was 59 months. The Consist of malignant neoplasms, gastric cancer 39 cases, colon cancer 26 cases, lung cancer 24 cases, hepatocellular carcinoma 13 cases, breast cancer 13 cases, prostate carcinoma 10 cases, and 18 kind of diagnosis 64 cases. On the other hand, kind of malignant lymphoma, Hodgkin`s lymphoma 7 cases, non-Hodgkin`s lymphoma 153 cases, adult T cell lymphoma 1 case. Median overall survival time was 33 months. About double neoplasms, median overall survival time between metachronous and synchronous type, there is signifi cance difference. Conclusions: In metachronous double type, all cases were102, 41 cases out of 102 cases were diagnosed within 5 years. We can discover metachronous multiple neoplasms by serial observations of fi ve years from an initial diagnosis.